Pub Date : 2019-01-01DOI: 10.17925/usor.2019.12.2.96
Luke Y. Chang, J. Hess, Z. Lukowski, Amy J. Estes
{"title":"Making the Perfect Winter Wonderland—A Case Report of Infectious Crystalline Keratopathy in the Setting of Chronic Nepafenac Use for Cystoid Macular Edema","authors":"Luke Y. Chang, J. Hess, Z. Lukowski, Amy J. Estes","doi":"10.17925/usor.2019.12.2.96","DOIUrl":"https://doi.org/10.17925/usor.2019.12.2.96","url":null,"abstract":"<p />","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.17925/usor.2019.12.2.69
J. Avaylon, R. Gallemore
{"title":"Verteporfin Photodynamic Therapy for the Treatment of Choroidal Conditions—An Overview","authors":"J. Avaylon, R. Gallemore","doi":"10.17925/usor.2019.12.2.69","DOIUrl":"https://doi.org/10.17925/usor.2019.12.2.69","url":null,"abstract":"<p />","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67621784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.17925/usor.2019.12.1.28
Eileen Choudhury, Joseph F. Panarelli
{"title":"A Review of Recent Landmark Trials in Glaucoma","authors":"Eileen Choudhury, Joseph F. Panarelli","doi":"10.17925/usor.2019.12.1.28","DOIUrl":"https://doi.org/10.17925/usor.2019.12.1.28","url":null,"abstract":"<p />","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67621680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-01-01DOI: 10.17925/usor.2019.12.2.88
K. Stonecipher, G. Torkildsen, E. McLaurin, Linda Villanueva, G. Ousler, D. Hollander, Greensboro Nc Usa Tlc Laser Eye Centers
{"title":"Efficacy and Safety of Topical Cyclosporine in Dry Eye Subjects Who Engage in Electronic Visual Tasking—The EMPOWER Study","authors":"K. Stonecipher, G. Torkildsen, E. McLaurin, Linda Villanueva, G. Ousler, D. Hollander, Greensboro Nc Usa Tlc Laser Eye Centers","doi":"10.17925/usor.2019.12.2.88","DOIUrl":"https://doi.org/10.17925/usor.2019.12.2.88","url":null,"abstract":"<p />","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/usor.2018.11.1.47
B. Turgut, O. Çatak, T. Demir
Choroidal nevus and choroidal malignant melanoma, especially when they are small in size, may have similar ophthalmoscopic appearance. Additionally, though rarely, choroidal nevi may convert to malignant melanomas over several years. Early detection of a small choroidal malignant melanomas presents the risk of growth, and metastasis is extremely critical for the preservation of both vision and eye. Currently, the usage of the mnemonic TFSOM-HHD has been suggested to find small ocular melanomas using helpful hints daily. In this review, we aim to provide the main discriminator and diagnostic features for choroidal malignant melanoma and choroidal nevus.
{"title":"Discriminator and Diagnostic Features for Choroidal Malignant Melanoma and Choroidal Nevus","authors":"B. Turgut, O. Çatak, T. Demir","doi":"10.17925/usor.2018.11.1.47","DOIUrl":"https://doi.org/10.17925/usor.2018.11.1.47","url":null,"abstract":"Choroidal nevus and choroidal malignant melanoma, especially when they are small in size, may have similar ophthalmoscopic appearance. Additionally, though rarely, choroidal nevi may convert to malignant melanomas over several years. Early detection of a small choroidal malignant melanomas presents the risk of growth, and metastasis is extremely critical for the preservation of both vision and eye. Currently, the usage of the mnemonic TFSOM-HHD has been suggested to find small ocular melanomas using helpful hints daily. In this review, we aim to provide the main discriminator and diagnostic features for choroidal malignant melanoma and choroidal nevus.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"11 1","pages":"47"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67620868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/USOR.2018.11.2.81
A. Banker, C. Pavesio, P. Merrill, B. Clinic
The primary goals of treatment in patients with non-infectious uveitis (NIU) are to control ocular inflammation and prevent sight-threatening complications such as macular edema and glaucoma. Systemic corticosteroids are the mainstay of treatment in NIU of the posterior segment (NIU-PS); however, long-term use is associated with treatment-limiting adverse effects. The need for agents with improved safety and tolerability coupled with recent insights into the pathogenesis of NIU-PS have led to the development of novel targeted interventions that potentially reduce or eliminate systemic corticosteroid exposure. Targeted interventions include intraocular drug delivery systems that provide high local concentrations at the site of inflammation with low systemic exposure and therapeutic agents, such as monoclonal antibodies that target specific pro-inflammatory cytokines and cytokine-mediated signaling pathways. The expanding range of therapeutic options enhances the ability to tailor therapy according to individual patient circumstances and optimize outcomes in patients with NIU-PS.
{"title":"Emerging Treatments for Non-infectious Uveitis","authors":"A. Banker, C. Pavesio, P. Merrill, B. Clinic","doi":"10.17925/USOR.2018.11.2.81","DOIUrl":"https://doi.org/10.17925/USOR.2018.11.2.81","url":null,"abstract":"The primary goals of treatment in patients with non-infectious uveitis (NIU) are to control ocular inflammation and prevent sight-threatening complications such as macular edema and glaucoma. Systemic corticosteroids are the mainstay of treatment in NIU of the posterior segment (NIU-PS); however, long-term use is associated with treatment-limiting adverse effects. The need for agents with improved safety and tolerability coupled with recent insights into the pathogenesis of NIU-PS have led to the development of novel targeted interventions that potentially reduce or eliminate systemic corticosteroid exposure. Targeted interventions include intraocular drug delivery systems that provide high local concentrations at the site of inflammation with low systemic exposure and therapeutic agents, such as monoclonal antibodies that target specific pro-inflammatory cytokines and cytokine-mediated signaling pathways. The expanding range of therapeutic options enhances the ability to tailor therapy according to individual patient circumstances and optimize outcomes in patients with NIU-PS.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"15 1","pages":"81"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/USOR.2018.11.2.98
Gerardo González-Saldivar, D. Chow
Disclosures: Gerardo González-Saldivar has nothing to declare in relation to this article. David R Chow declares the following financial interests or relationships: consultant/advisor for Alcon Laboratories, Inc., Bayer Healthcare Pharmaceuticals, Dutch Ophthalmic Research Center (DORC) International USA and Katalyst; lecture fees for DORC International USA, OptoVue and Allergan; and equity ownership/stock options in public or privately traded firms, excluding mutual funds from Katalyst and Synergetics, Inc.
披露:Gerardo González-Saldivar没有任何与本文相关的声明。David R Chow声明以下财务利益或关系:Alcon Laboratories, Inc.， Bayer Healthcare Pharmaceuticals, Dutch Ophthalmic Research Center (DORC) International USA和catalyst的顾问/顾问;DORC International USA、OptoVue、Allergan讲座费用;上市或私人交易公司的股权/股票期权，不包括来自catalyst and synergtics, Inc.的共同基金。
{"title":"Update in Vitreoretinal Instrumentation","authors":"Gerardo González-Saldivar, D. Chow","doi":"10.17925/USOR.2018.11.2.98","DOIUrl":"https://doi.org/10.17925/USOR.2018.11.2.98","url":null,"abstract":"Disclosures: Gerardo González-Saldivar has nothing to declare in relation to this article. David R Chow declares the following financial interests or relationships: consultant/advisor for Alcon Laboratories, Inc., Bayer Healthcare Pharmaceuticals, Dutch Ophthalmic Research Center (DORC) International USA and Katalyst; lecture fees for DORC International USA, OptoVue and Allergan; and equity ownership/stock options in public or privately traded firms, excluding mutual funds from Katalyst and Synergetics, Inc.","PeriodicalId":90077,"journal":{"name":"US ophthalmic review","volume":"11 1","pages":"98"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67622087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：